<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02160145</url>
  </required_header>
  <id_info>
    <org_study_id>156-13-210</org_study_id>
    <nct_id>NCT02160145</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease</brief_title>
  <official_title>A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether tolvaptan is effective and safe for the
      treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney
      disease (ADPKD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol will extend the understanding of the efficacy and safety of tolvaptan treatment
      in ADPKD patients with late stage 2 to early stage 4 CKD (chronic kidney disease).

      This trial will compare the efficacy of tolvaptan treatment in reducing the annualized change
      in estimated glomerular filtration rate (eGFR) from pre-treatment baseline to post-treatment
      follow-up, as compared with placebo, in subjects who tolerate tolvaptan during an initial
      run-in period. The change in eGFR, calculated by the Chronic Kidney Disease-Epidemiology
      (CKD-EPI) formula, will provide kidney function data that are complementary to the data
      demonstrating the benefits previously observed primarily in ADPKD subjects with earlier
      stages of disease.

      Also, it will compare the efficacy of tolvaptan treatment in reducing the decline of
      annualized eGFR slope, as compared with placebo, in this type of subjects. Finally, it will
      compare the overall and hepatic safety profile of tolvaptan with placebo and to compare
      incidence of ADPKD complications (outcomes) during the trial
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">April 18, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up.</measure>
    <time_frame>Pretreatment baseline to post-treatment follow-up (up to 61 weeks).</time_frame>
    <description>The mean annualized change in eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula from pretreatment baseline to post-treatment follow-up, annualized (divided) by each subject's trial duration.
The baseline for the primary endpoint was defined as the average of up to 3 eGFR values observed during the screening and placebo run-in periods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Annualized Slope of eGFR Change</measure>
    <time_frame>Pretreatment baseline to post-treatment follow-up (up to 61 weeks).</time_frame>
    <description>To compare the efficacy of tolvaptan treatment in reducing the decline of annualized eGFR slope, as compared with placebo, in subjects with late-stage CKD due to ADPKD who tolerated tolvaptan during an initial run-in period, the annualized rate of eGFR change was derived from each individual subject's eGFR slope using the CKD-EPI formula.
The annualized eGFR change slope was derived from all eGFR observations from placebo-run-in, tolvaptan run-in, double-blind treatment and post-treatment follow-up periods using the linear mixed model of analysis. The mean annualized slope of eGFR change is presented.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up</measure>
    <time_frame>Baseline and Months 3, 6, 9 and 12 (End of treatment visit) of the double-blind treatment period, and post-treatment follow-up.</time_frame>
    <description>The mean change from baseline in urine osmolality for the double-blind treatment period collection timepoints and post-treatment follow-up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up</measure>
    <time_frame>Baseline and Months 3, 6, 9 and 12 (End of treatment visit) of the double-blind treatment period, and post-treatment follow-up.</time_frame>
    <description>The mean change from baseline in urine specific gravity for the double-blind treatment period collection timepoints and post-treatment follow up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1370</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolvaptan (OPC-41061)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan (OPC-41061)</intervention_name>
    <description>Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.</description>
    <arm_group_label>Tolvaptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with eGFR between 25-65 mL/min/1.73m2 (if aged 18 to55) or
             eGFR between 25-44 mL/min/1.73m2 (if aged 56 to &lt;66)

          -  Tolvaptan na√Øve

          -  Diagnosis of ADPKD by modified pei-Ravine criteria 1) 3 cysts per kidney by sonography
             or 5 cysts by CT or MRI with family history of ADPKD or 2) 10 cysts per kidney by any
             radiologic method and exclusion of other cystic kidney diseases if without family
             history

        Exclusion Criteria:

          -  Women of childbearing potential who do not agree to practice 2 different methods of
             birth control or remain abstinent during the trial and for 30 days after the last dose
             of Investigational medicinal product (IMP)

          -  Women who are breast-feeding and/or who have a positive pregnancy test prior to
             receiving IMP

          -  Need for chronic diuretic use

          -  Hepatic impairment or liver function abnormalities other than that expected for ADPKD
             with typical cystic liver disease

          -  Advanced diabetes, evidence of additional significant renal disease, renal cancer,
             single kidney, recent renal surgery or acute kidney injury

          -  Contraindications to required trial assessments

          -  Medical history or medical findings inconsistent with safety or compliance with trial
             assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hudson</city>
        <state>Florida</state>
        <zip>34667</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosedale</city>
        <state>New York</state>
        <zip>11422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>98686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>39723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bahia Blanca</city>
        <state>Buenos Aires</state>
        <zip>B8000FTD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma</city>
        <state>Buenos Aires</state>
        <zip>C1093AAS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma</city>
        <state>Buenos Aires</state>
        <zip>C1119ACN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma</city>
        <state>Buenos Aires</state>
        <zip>C1425APQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma</city>
        <state>Buenos Aires</state>
        <zip>C1429BWN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma</city>
        <state>Buenos Aires</state>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Junin</city>
        <state>Buenos Aires</state>
        <zip>6000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pergamino</city>
        <state>Buenos Aires</state>
        <zip>B2700CPM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarandi</city>
        <state>Buenos Aires</state>
        <zip>B1872EEA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reservoir</city>
        <state>Victoria</state>
        <zip>3073</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Li√®ge</city>
        <zip>400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1H 3G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 5T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jilemnice</city>
        <zip>51401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liberec</city>
        <zip>460 63</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tabor</city>
        <zip>390 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest cedex 2</city>
        <state>Finistere</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux Cedex</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse Cedex 9</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier cedex 5</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble cedex 9</city>
        <state>Isere</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Priest-En-Jarez</city>
        <state>Loire</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims Cedex</city>
        <state>Marne</state>
        <zip>51090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Meurthe Et Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon Cedex 03</city>
        <state>Rhone</state>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre-B√©nite cedex</city>
        <state>Rhone</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nuernberg</city>
        <state>Bayern</state>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein Westfalen</state>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <state>Nordrhein Westfalen</state>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peta·∫ñ Tiqwa</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>34239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrette Di Ancona</city>
        <state>Ancona</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montichiari</city>
        <state>Brescia</state>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciechanow</city>
        <zip>06-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Golub Dobrzyn</city>
        <zip>87-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krak√≥w</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>≈Å√≥d≈∫</city>
        <zip>92-313</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <zip>011794</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradea</city>
        <zip>410649</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>G√∂teborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Link√∂ping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>√ñrebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hull</city>
        <state>East Riding Of Yorkshire</state>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stevenage</city>
        <state>Hertfordshire</state>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inverness</city>
        <state>Highland Region</state>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <state>Lothian Region</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middlesbrough</city>
        <state>North Yorkshire</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stoke-on-Trent</city>
        <state>Staffordshire</state>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coventry</city>
        <state>Warwickshire</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <results_first_submitted>May 1, 2018</results_first_submitted>
  <results_first_submitted_qc>July 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2018</results_first_posted>
  <disposition_first_submitted>September 18, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 18, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 26, 2017</disposition_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02160145/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02160145/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject first visit: 21 May 2014; Last subject last visit: 18 April 2017. Subjects were recruited from 213 sites in 21 countries. Of 2292 subjects screened, 1519 entered the 6-week run-in period; 23 were placebo run-in failures and 126 were tolvaptan titration/run-in failures.</recruitment_details>
      <pre_assignment_details>Subjects with Stage 2 - 4 chronic kidney disease (CKD) due to Autosomal Dominant Polycystic Kidney Disease (ADPKD) were stratified by baseline estimated glomerular filtration rate (eGFR) (‚â§ 45 or &gt; 45 milliliters/minute/ 1.73 square metres [mL/min/1.73 m^2]), by age (‚â§ 55 or &gt; 55 years), and total kidney volume (‚â§ 2000 mL, &gt; 2000 mL, or unknown).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects Prerandomization</title>
          <description>Following screening, the single-blind prerandomization period (Day -42 to Day -1) consisted of:
Placebo Run-in: All subjects received a daily split-dose of placebo (0/0 milligrams [mg]) in a form identical to 15/15 mg tolvaptan split-dose for 1 week.
Tolvaptan Titration: Over 2 weeks all subjects received a split-dose of 30/15 mg (2 x 15mg tablets upon waking, then 1 x 15 mg tablet 8-9 hours later) which was titrated up every 3-4 days to 45/15 mg, then 60/30 mg, and up to a maximum dose of 90/30 mg.
Tolvaptan Run-in: Eligible subjects who tolerated at least 60/30 mg tolvaptan during titration entered the 3-week run-in period and continued on a stable dose of 60/30 mg or 90/30 mg tolvaptan to confirm eligibility and establish prerandomization baseline.</description>
        </group>
        <group group_id="P2">
          <title>Tolvaptan</title>
          <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects continued on the same dose of tolvaptan they received during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Double-blind Randomized Treatment Period (Day 0 to Month 12):
Following randomization subjects received placebo tablets matching their tolerated tolvaptan dose during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Prerandomization Single-blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1519"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated in Placebo Run-in</title>
              <participants_list>
                <participants group_id="P1" count="1514"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated in Tolvaptan Titration/Run-in</title>
              <participants_list>
                <participants group_id="P1" count="1491"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized</title>
              <participants_list>
                <participants group_id="P1" count="1370"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1370"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Placebo run-in failure</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tolvaptan titration/run-in failure</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Randomized Double-blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">1370 subjects were randomized to receive tolvaptan or placebo in the double-blind period.</participants>
                <participants group_id="P2" count="683">Subjects completed the single-blind period and were randomized to receive tolvaptan.</participants>
                <participants group_id="P3" count="687">Subjects completed the single-blind period and were randomized to receive placebo.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>On-treatment Completers</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="578"/>
                <participants group_id="P3" count="637"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Off-treatment Completers</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="654"/>
                <participants group_id="P3" count="659"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline population consisted of all randomized subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Tolvaptan</title>
          <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects continued on the same dose of tolvaptan they received during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects received placebo tablets matching their tolerated tolvaptan dose during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
        </group>
        <group group_id="B3">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="683"/>
            <count group_id="B2" value="687"/>
            <count group_id="B3" value="1370"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" spread="8.2"/>
                    <measurement group_id="B2" value="47.2" spread="8.2"/>
                    <measurement group_id="B3" value="47.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="354"/>
                    <measurement group_id="B3" value="690"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="347"/>
                    <measurement group_id="B2" value="333"/>
                    <measurement group_id="B3" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="632"/>
                    <measurement group_id="B2" value="647"/>
                    <measurement group_id="B3" value="1279"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="626"/>
                    <measurement group_id="B2" value="632"/>
                    <measurement group_id="B3" value="1258"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up.</title>
        <description>The mean annualized change in eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula from pretreatment baseline to post-treatment follow-up, annualized (divided) by each subject's trial duration.
The baseline for the primary endpoint was defined as the average of up to 3 eGFR values observed during the screening and placebo run-in periods.</description>
        <time_frame>Pretreatment baseline to post-treatment follow-up (up to 61 weeks).</time_frame>
        <population>The primary endpoint efficacy population consisted of all subjects who were in the randomized sample, took at least 1 dose of investigational medicinal product (IMP) after randomization, and had a baseline and at least 1 valid post-treatment evaluation in eGFR (i.e at least 1 week off-treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan</title>
            <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects continued on the same dose of tolvaptan they received during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects received placebo tablets matching their tolerated tolvaptan dose during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Annualized Change in eGFR From Pretreatment Baseline to Post-treatment Follow-up.</title>
          <description>The mean annualized change in eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula from pretreatment baseline to post-treatment follow-up, annualized (divided) by each subject's trial duration.
The baseline for the primary endpoint was defined as the average of up to 3 eGFR values observed during the screening and placebo run-in periods.</description>
          <population>The primary endpoint efficacy population consisted of all subjects who were in the randomized sample, took at least 1 dose of investigational medicinal product (IMP) after randomization, and had a baseline and at least 1 valid post-treatment evaluation in eGFR (i.e at least 1 week off-treatment).</population>
          <units>mL/min/1.73 m^2/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="668"/>
                <count group_id="O2" value="663"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.339" spread="0.240"/>
                    <measurement group_id="O2" value="-3.610" spread="0.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tolvaptan versus placebo. Treatment difference in the change of eGFR assessed the efficacy of tolvaptan treatment as compared with placebo in subjects with late-stage CKD due to ADPKD who tolerated tolvaptan during an initial run-in period.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A 2-sided alpha of 0.05 was applied to the primary analysis of the primary endpoint.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Weighted Analysis of Covariance (ANCOVA) with effects of treatment and randomization stratification factors and covariate baseline.</method_desc>
            <param_type>Treatment difference</param_type>
            <param_value>1.271</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.859</ci_lower_limit>
            <ci_upper_limit>1.684</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Annualized Slope of eGFR Change</title>
        <description>To compare the efficacy of tolvaptan treatment in reducing the decline of annualized eGFR slope, as compared with placebo, in subjects with late-stage CKD due to ADPKD who tolerated tolvaptan during an initial run-in period, the annualized rate of eGFR change was derived from each individual subject's eGFR slope using the CKD-EPI formula.
The annualized eGFR change slope was derived from all eGFR observations from placebo-run-in, tolvaptan run-in, double-blind treatment and post-treatment follow-up periods using the linear mixed model of analysis. The mean annualized slope of eGFR change is presented.</description>
        <time_frame>Pretreatment baseline to post-treatment follow-up (up to 61 weeks).</time_frame>
        <population>The key secondary endpoint efficacy population consisted of all randomized subjects who took at least 1 dose of IMP after randomization, and have a baseline (average of up to 3 eGFR values observed during screening and placebo run-in periods) and at least 1 post-randomization evaluation in eGFR during the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan</title>
            <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects continued on the same dose of tolvaptan they received during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects received placebo tablets matching their tolerated tolvaptan dose during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Annualized Slope of eGFR Change</title>
          <description>To compare the efficacy of tolvaptan treatment in reducing the decline of annualized eGFR slope, as compared with placebo, in subjects with late-stage CKD due to ADPKD who tolerated tolvaptan during an initial run-in period, the annualized rate of eGFR change was derived from each individual subject's eGFR slope using the CKD-EPI formula.
The annualized eGFR change slope was derived from all eGFR observations from placebo-run-in, tolvaptan run-in, double-blind treatment and post-treatment follow-up periods using the linear mixed model of analysis. The mean annualized slope of eGFR change is presented.</description>
          <population>The key secondary endpoint efficacy population consisted of all randomized subjects who took at least 1 dose of IMP after randomization, and have a baseline (average of up to 3 eGFR values observed during screening and placebo run-in periods) and at least 1 post-randomization evaluation in eGFR during the double-blind treatment period.</population>
          <units>mL/min/1.73m^2/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="680"/>
                <count group_id="O2" value="682"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.160" spread="0.140"/>
                    <measurement group_id="O2" value="-4.170" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in treatment effect was derived from a linear mixed model with effects of treatment, time, treatment ime interaction, acute haemodynamic effect, pretreatment baseline, and randomization stratification factors. An unstructured variance matrix was assumed for the random intercept and time.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A two-sided alpha of 0.05 was applied when the primary endpoint reached a two-sided alpha of 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment difference</param_type>
            <param_value>1.011</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.618</ci_lower_limit>
            <ci_upper_limit>1.403</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up</title>
        <description>The mean change from baseline in urine osmolality for the double-blind treatment period collection timepoints and post-treatment follow-up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.</description>
        <time_frame>Baseline and Months 3, 6, 9 and 12 (End of treatment visit) of the double-blind treatment period, and post-treatment follow-up.</time_frame>
        <population>The primary safety population consisted of all subjects who were randomized and took at least 1 dose of IMP after randomization. Only subjects with data available for analysis at the timepoints of testing are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan</title>
            <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects continued on the same dose of tolvaptan they received during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects received placebo tablets matching their tolerated tolvaptan dose during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Urine Osmolality During the Double-blind Treatment Period and Post-treatment Follow-up</title>
          <description>The mean change from baseline in urine osmolality for the double-blind treatment period collection timepoints and post-treatment follow-up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.</description>
          <population>The primary safety population consisted of all subjects who were randomized and took at least 1 dose of IMP after randomization. Only subjects with data available for analysis at the timepoints of testing are presented.</population>
          <units>milliosmole per kilogram (mOSm/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="681"/>
                <count group_id="O2" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="655"/>
                    <count group_id="O2" value="664"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="80.3"/>
                    <measurement group_id="O2" value="177.7" spread="124.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="637"/>
                    <count group_id="O2" value="652"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="84.3"/>
                    <measurement group_id="O2" value="179.1" spread="126.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="625"/>
                    <count group_id="O2" value="646"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="92.1"/>
                    <measurement group_id="O2" value="179.9" spread="125.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="629"/>
                    <count group_id="O2" value="651"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="96.0"/>
                    <measurement group_id="O2" value="180.3" spread="121.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="624"/>
                    <count group_id="O2" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.4" spread="114.0"/>
                    <measurement group_id="O2" value="179.5" spread="128.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up</title>
        <description>The mean change from baseline in urine specific gravity for the double-blind treatment period collection timepoints and post-treatment follow up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.</description>
        <time_frame>Baseline and Months 3, 6, 9 and 12 (End of treatment visit) of the double-blind treatment period, and post-treatment follow-up.</time_frame>
        <population>The primary safety population consisted of all subjects who were randomized and took at least 1 dose of IMP after randomization. Only subjects with data available for analysis at the timepoints of testing are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan</title>
            <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects continued on the same dose of tolvaptan they received during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Randomized Treatment Period (Day 0 to Month 12): Following randomization subjects received placebo tablets matching their tolerated tolvaptan dose during the tolvaptan run-in period (60/30 mg or 90/30 mg) for a duration of 12 months.
Follow-up Period: A 3-week final follow-up for efficacy analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Urine Specific Gravity During the Double-blind Treatment Period and Post-treatment Follow-up</title>
          <description>The mean change from baseline in urine specific gravity for the double-blind treatment period collection timepoints and post-treatment follow up are presented. Baseline was defined as the last evaluation prior to post-randomization dosing.</description>
          <population>The primary safety population consisted of all subjects who were randomized and took at least 1 dose of IMP after randomization. Only subjects with data available for analysis at the timepoints of testing are presented.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="681"/>
                <count group_id="O2" value="685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="654"/>
                    <count group_id="O2" value="662"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" spread="0.0022"/>
                    <measurement group_id="O2" value="0.0041" spread="0.0033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="638"/>
                    <count group_id="O2" value="649"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0003" spread="0.0024"/>
                    <measurement group_id="O2" value="0.0042" spread="0.0033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="623"/>
                    <count group_id="O2" value="641"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.0025"/>
                    <measurement group_id="O2" value="0.0040" spread="0.0032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="635"/>
                    <count group_id="O2" value="648"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0006" spread="0.0027"/>
                    <measurement group_id="O2" value="0.0040" spread="0.0033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="620"/>
                    <count group_id="O2" value="653"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0037" spread="0.0031"/>
                    <measurement group_id="O2" value="0.0040" spread="0.0034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the tolvaptan single-blind period: 35 days (Day -35 to Day -1). For the double-blind treatment period: 12 months (Day 0 to 12 months).</time_frame>
      <desc>Treatment emergent adverse events (AEs) were collected, defined as an AE that started after IMP treatment or an AE that was continuous from baseline and was serious, IMP related or resulted in death, discontinuation, interruption or reduction of IMP treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tolvaptan (Single-blind Treatment Period)</title>
          <description>The secondary safety population consisted of all subjects who took at least one dose of tolvaptan during the tolvaptan titration/run-in periods.</description>
        </group>
        <group group_id="E2">
          <title>Tolvaptan (Double-blind Treatment Period)</title>
          <description>The tolvaptan primary safety population consisted of all subjects who were randomized in the double-blind treatment period and who took at least one dose of tolvaptan after randomization.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Double-blind Treatment Period)</title>
          <description>The placebo primary safety population consisted of all subjects who were randomized in the double-blind treatment period and who took at least one dose of placebo after randomization.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1491"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="681"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Hepatic Fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Abdominal Incarcerated Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Cyst rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Haemorrhagic hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1491"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hepatic cyst infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Procedural intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1491"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="681"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Vitamin B complex deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Cerebral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1491"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Renal cyst haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1491"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="681"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="681"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Rash Maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1051" subjects_at_risk="1491"/>
                <counts group_id="E2" subjects_affected="581" subjects_at_risk="681"/>
                <counts group_id="E3" subjects_affected="564" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="134" subjects_affected="132" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="54" subjects_affected="47" subjects_at_risk="681"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="453" subjects_affected="430" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="49" subjects_affected="46" subjects_at_risk="681"/>
                <counts group_id="E3" events="27" subjects_affected="24" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="37" subjects_affected="30" subjects_at_risk="681"/>
                <counts group_id="E3" events="50" subjects_affected="45" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="70" subjects_affected="59" subjects_at_risk="681"/>
                <counts group_id="E3" events="71" subjects_affected="58" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="48" subjects_affected="39" subjects_at_risk="681"/>
                <counts group_id="E3" events="65" subjects_affected="55" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="98" subjects_affected="72" subjects_at_risk="681"/>
                <counts group_id="E3" events="111" subjects_affected="84" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="58" subjects_affected="46" subjects_at_risk="681"/>
                <counts group_id="E3" events="56" subjects_affected="46" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="147" subjects_affected="146" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="681"/>
                <counts group_id="E3" events="46" subjects_affected="41" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="66" subjects_affected="55" subjects_at_risk="681"/>
                <counts group_id="E3" events="65" subjects_affected="59" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="319" subjects_affected="308" subjects_at_risk="1491"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="681"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="488" subjects_affected="475" subjects_at_risk="1491"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="681"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="52" subjects_affected="37" subjects_at_risk="681"/>
                <counts group_id="E3" events="42" subjects_affected="35" subjects_at_risk="685"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="158" subjects_affected="113" subjects_at_risk="681"/>
                <counts group_id="E3" events="174" subjects_affected="130" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1491"/>
                <counts group_id="E2" events="88" subjects_affected="73" subjects_at_risk="681"/>
                <counts group_id="E3" events="96" subjects_affected="79" subjects_at_risk="685"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Devlopment</name_or_title>
      <organization>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</organization>
      <phone>609 524 6788</phone>
      <email>clinicaltransparency@otsuka-us.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

